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We investigated epidemiologic and clinical aspects of 
rickettsial diseases in 280 international travelers reported to 
the GeoSentinel Surveillance Network during 1996–2008. 
Of these 280 travelers, 231 (82.5%) had spotted fever 
(SFG) rickettsiosis, 16 (5.7%) scrub typhus, 11 (3.9%) Q 
fever, 10 (3.6%) typhus group (TG) rickettsiosis, 7 (2.5%) 
bartonellosis, 4 (1.4%) indeterminable SFG/TG rickettsio-
sis, and 1 (0.4%) human granulocytic anaplasmosis. One 
hundred ninety-seven (87.6%) SFG rickettsiosis cases 
were acquired in sub-Saharan Africa and were associated 
with higher age, male gender, travel to southern Africa, late 
summer season travel, and travel for tourism. More than 
90% of patients with rickettsial disease were treated with 
doxycycline, 43 (15.4%) were hospitalized, and 4 had a 
complicated course, including 1 fatal case of scrub typhus 
encephalitis acquired in Thailand. 
R
ickettsial diseases are acute and potentially severe 
zoonotic infections caused by obligate intracellular, 
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gram-negative bacteria belonging to the order Rickettsiales. 
The taxonomy of Rickettsiales is complex and continues to 
be updated, but currently the agents of rickettsial diseases 
are classiﬁ  ed as belonging to 4 distinct genera: Rickettsia 
(including 2 biogroups: spotted fever group [SFG] rickettsi-
ae with >10 species and typhus group [TG] rickettsiae with 
2 species), Orientia (Orientia tsutsugamushi, the agent of 
scrub typhus), Ehrlichia (Ehrlichia chaffeensis, the agent 
of human monocytic ehrlichiosis), and Anaplasma (Ana-
plasma phagocytophilium, the agent of human granulocytic 
anaplasmosis). Diseases caused by Rickettsia and Orientia 
species are often collectively referred to as rickettsioses. 
Coxiella burnetii, the agent of Q fever, and Bartonella spp. 
were recently removed from the order Rickettsiales, but Q 
fever and bartonelloses are still frequently categorized as 
rickettsial diseases (1).
Rickettsial diseases are increasingly being recognized 
among international travelers (2). A recent study of ≈7,000 
returnees with fever as a chief reason to seek medical care 
suggests that 2% of imported fevers are caused by rick-
ettsioses and that 20% of these patients are hospitalized (3). 
Most cases are acquired in sub-Saharan Africa, where SFG 
rickettsioses are second only to malaria as the most com-
monly diagnosed diseases in returnees with systemic febrile 
illness (4). With few exceptions, however, our knowledge 
of the incidence rates, associated factors, signs, symptoms, 
and outcome of rickettsial diseases in travelers is rudimen-
tary and mostly based on smaller case series. We report all 
cases of rickettsial diseases in returned travelers reported 
to the GeoSentinel Surveillance Network from June 1996 
through December 2008.
Materials and Methods
Data Source
GeoSentinel is a global network aimed at survey-
ing ill international travelers and was established in 1995 
through the International Society of Travel Medicine and 
the Centers for Disease Control and Prevention. The 41 
current GeoSentinel sites contribute clinician-based, anon-
ymous information on all ill travelers seen that is entered 
in a structured query language database at a central data 
center. Data collected include demographic information, 
recent travel history, reason for travel, outpatient or inpa-
tient status, whether the patient was seen during or after 
travel, whether the patient traveled independently versus 
organized travel (i.e., travel with a tour group), whether the 
patient had pretravel encounter with a healthcare provider, 
patient symptoms, and diagnosis. All GeoSentinel sites 
use the best reference diagnostic methods available in the 
country where the site is located. The diagnosis, which may 
be reported as conﬁ  rmed, probable, or suspected, is chosen 
from a standardized list of >500 possible etiologic and syn-
dromic diagnoses, 11 of which refer to rickettsial diseases. 
Patients may receive several diagnoses, some of which 
describe well-known complications of rickettsial diseases, 
e.g., acute renal failure, acute encephalitis, acute respira-
tory distress syndrome, and death (3,4). The GeoSentinel 
questionnaire does not contain queries about case man-
agement, but in December 2008 all sites were requested 
to estimate the percentage of their patients with rickettsial 
diseases who received treatment with antirickettsial drugs 
(e.g., doxycycline) during the study period.
Inclusion Criteria and Deﬁ  nitions
Data entered into the GeoSentinel database from June 
1996 through December 2008 were reviewed. Only trav-
elers seen with conﬁ  rmed or probable diagnoses were in-
cluded in the analysis. Cases of rickettsial diseases were 
deﬁ  ned according to the criteria mentioned below. A sub-
analysis, comparing SFG rickettsioses with other diseases 
in ill returnees from sub-Saharan Africa, was also per-
formed (Figure 1).
A microbiologic diagnosis of recent rickettsial disease 
was in most cases based on immunoﬂ  uorescence antibody 
(IFA) tests and, occasionally, on PCR and Western blot. 
Diagnostic criteria of recent infection by IFA tests were 
either a 4-fold increase of immunoglobulin (Ig) G or IgM 
titers in paired serum samples drawn >10 days apart, or 
elevated IgG and/or IgM titers in single samples consis-
tent with recent infection as interpreted by the local micro-
biology laboratory. Because IFA tests cannot distinguish 
between species within the same Rickettsia biogroup, dis-
eases caused by Rickettsia species were dichotomized as 
SFG rickettsiosis and TG rickettsiosis.
We included all cases of conﬁ  rmed rickettsial disease 
deﬁ  ned as a traveler with pertinent travel history and clini-
cal signs, and microbiologic test results supporting recent 
infection. For SFG rickettsiosis and scrub typhus we also 
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All GeoSentinel cases, 1996–2008 
N = 99,355 
Cases included in analysis: 
N = 47,915
Cases excluded: N = 51,440 
Travel for immigration only: n = 15,715 
Seen during travel: n = 30,956 
Other reasons: n = 4,769
With rickettsial diseases: 
n = 280 
With other diseases: 
n = 47,635 
With rickettsial diseases acquired 
in sub-Saharan Africa: n = 205 
Acquired outside sub-Saharan Africa 
or missing exposure: n = 35,956 
Acquired outside sub-Saharan Africa 
or missing exposure: n = 75 
With SFG rickettsioses acquired in  
sub-Saharan Africa: n = 197 
With other diseases than SFG rickettsioses 
acquired in sub-Saharan Africa: n = 11,690 
With rickettsial 
diseases other than 
SFG rickettsioses: 
n = 8 
Figure 1. Study design with main study (above dotted line) 
and substudy (below dotted line) of spotted fever group (SFG) 
rickettsiosis acquired in sub-Saharan Africa, 1996–2008.GeoSentinel Analysis of Rickettsial Diseases
included probable cases deﬁ  ned as a traveler with pertinent 
travel history and clinical signs including >1 inoculation 
eschars, and inconclusive or unavailable microbiologic test 
results. Cases were categorized in 9 disease groups: SFG 
rickettsiosis, TG rickettsiosis, indeterminate SFG/TG rick-
ettsiosis (deﬁ  ned as cases in whom neither clinical signs 
nor microbiologic tests could distinguish between SFG and 
TG rickettsiosis), scrub typhus, ehrlichiosis, anaplasmosis, 
acute and chronic Q fever (based on the presence of anti-
bodies to the 2 distinct antigenic phases of C. burnetii by 
IFA test [5]), and bartonellosis. Countries were grouped 
according to the United Nations region system, and for 
sub-Saharan Africa also in subregions; for clariﬁ  cation, the 
southern Africa subregion included Botswana, Lesotho, 
Namibia, South Africa, and Swaziland. Classiﬁ  cation of 
reason for travel related to current illness was grouped into 
4 categories: tourism, business, visiting friends and rela-
tives, and other reason, which included studies or military, 
missionary, or foreign aid deployment.
Statistical Analysis
All data were analyzed using SAS software, version 
9 (SAS Institute, Cary, NC, USA). Comparison of travel-
ers to sub-Saharan Africa with SFG rickettsioses with all 
other ill travelers to the same destination used the Student 
t test for continuous variables and Cochran-Mantel-Haen-
szel statistic for binary variables. The association between 
possible risk factors and a diagnosis of SFG rickettsioses 
acquired in sub-Saharan Africa was measured with odds 
ratios and 95% conﬁ  dence intervals. Variables included in 
the univariate analysis were mean age, male gender, travel 
to southern Africa, travel from March through May, travel 
>1 week, no pretravel clinic visit, independent travel, and 
tourism as reason for travel. Variables with a p value <0.05 
in the ﬁ  nal multivariate logistic regression model were con-
sidered signiﬁ  cant.
Proportionate morbidity for SFG rickettsiosis acquired 
in sub-Saharan Africa was deﬁ  ned as the number of cases 
as a proportion of all ill returned travelers from the region. 
Analysis of case reports over time was based on monthly 
proportionate morbidity, i.e., the number of patients with 
SFG rickettsiosis as a proportion of the number of all ill 
returned travelers attending any GeoSentinel site in that 
month. The monthly seasonality was based on aggregate 
data for that month over all years. The annual proportion-
ate morbidity for SFG rickettsiosis acquired in southern 
Africa from 1999 through 2008 was estimated in a similar 
way based on relevant cases for each year. The Cochran-
Armitage test was used for testing trend over years. This 
statistic tests for trend in binomial proportions across levels 
of a single factor or covariate and is appropriate for a con-
tingency table where the response variable has 2 levels and 
the explanatory variable is ordinal. A 1-sided p value <0.05 
would indicate a decreasing (with a negative statistic) or 
increasing (with a positive statistic) trend.
Results
We identiﬁ  ed 99,355 travelers who sought medical care 
at a GeoSentinel site during June 1996–December 2008. 
Among the 47,915 case-patients who met the study inclusion 
criteria, 280 (0.6%) had a diagnosis of rickettsial disease 
(Figure 1); among those having fever, the proportion was 
211/13,763 (1.5%). Of travelers with rickettsial disease 231 
(82.5%) had SFG rickettsioses, 16 (5.7%) scrub typhus, 11 
(3.9%) acute Q fever, 10 (3.6%) TG rickettsioses, 7 (2.5%) 
bartonelloses, 4 (1.4%) indeterminate TG/SFG rickettsioses, 
and 1 (0.4%) human granulocytic anaplasmosis; there were 
no cases of chronic Q fever and ehrlichiosis. Cases were re-
ported from 32 of the 41 active GeoSentinel sites: a total of 
154 (54.9%) were reported from sites in Europe, 77 (27.5%) 
from North America, 17 (6.0%) from New Zealand/Austra-
lia, and 32 (11.6%) from Asia, including the Middle East. 
Most cases were associated with travel to sub-Saharan Af-
rica (75.1%) (Table 1). A pretravel encounter with a health-
care provider was reported in 157 cases (58.4%). At least 
90% of cases of rickettsial diseases were estimated to have 
been treated with antirickettsial drugs (doxycycline in most 
cases, occasionally a ﬂ  ouroquinolone) at the reporting sites 
during the study period.
SFG Rickettsioses
Of the 231 cases of SFG rickettsioses (146 conﬁ  rmed 
and 85 probable) a total of 136 (58.9%) were men; the 
mean age was 43.4 years (median 45 years, range 33–53 
years). Tourists comprised 182 (78.8%), 28 (12.1%) had 
traveled for business, 6 (2.6%) were visiting friends and 
relatives, and 14 (6.1%) had traveled for other reasons. One 
hundred ninety-seven (87.6%) case-patients were infected 
in sub-Saharan Africa; South Africa (n = 135), Zimbabwe 
(n = 13), and Tanzania (n = 7) were the 3 most commonly 
reported countries of exposure (Table 1). The median time 
from travel to reporting to a GeoSentinel site was 8 days 
(range 4–12 days). Two case-patients, a 23-year-old French 
woman tourist to Mongolia in June 2008, and a 27-year-old 
Swiss woman student traveler to Corsica, France, in Octo-
ber 2008, were infected by Rickettsia slovaca conﬁ  rmed 
by PCR and Western blot. There were no deaths among 
the travelers with SFG rickettsioses, but 22 (9.6%) were 
hospitalized, and multiorgan failure with acute respiratory 
distress syndrome developed in 2 Israeli men 47 and 73 
years of age, respectively, after they traveled to India in 
October 2004.
Analysis of demographic and exposure variables for 
the 197 travelers to sub-Saharan Africa with SFG rick-
ettsiosis compared with 11,690 travelers to the same re-
gion with other diagnoses is shown in Table 2. A multi-
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variate logistic regression model was performed to analyze 
the effects on SFG rickettsiosis of risk factors including 
age, gender, travel to southern Africa, travel from March 
to May, travel duration longer than 7 days, no pretravel 
clinic visit, independent travel, and travel for tourism. 
Older age, male gender, travel to southern Africa, travel 
from March to May, and travel for tourism were found to 
be independently associated with SFG rickettsiosis. An 
analysis of monthly proportionate morbidity identiﬁ  ed a 
peak of cases in March, April, and May (Figure 2). The 
proportionate morbidity of cases with SFG rickettsiosis in 
ill returnees from southern Africa from 1999 through 2008 
was 139/1,017 (13.7%). The overall Cochran-Armitage 
trend test did not show statistically signiﬁ  cant change (p 
= 0.877, by 2-sided trend test). As shown in Figure 3, the 
annual proportionate morbidity increased and decreased 
twice over the years and did not maintain a monotone in-
creasing or decreasing pattern.
Other Rickettsial Diseases
The 10 travelers with TG rickettsiosis, of whom 6 were 
men, had a mean age of 28.0 years (median 25.5 years, 
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Table 1. Travel destinations of 280 travelers with rickettsial diseases, by destination and disease, as reported to GeoSentinel, 1996–
2008*
No. travelers 
Destination
SFG 
rickettsiosis 
TG
rickettsiosis 
Indeterminate
SFG/TG rickettsiosis 
Scrub
typhus  Anaplasmosis
Acute Q 
fever Bartonellosis
Western Europe  7 1 1 2 1
Eastern Europe 1
North Africa 3
Sub-Saharan Africa  197 1 5 1
Middle East  1 21
Northeast Asia  2 1 1
South central Asia  5 1 1 5
Southeast Asia  3 6 2 9 1
Australia/New Zealand  1 1
Oceania 1
North America 1
Central America 3
Caribbean 1 3
South America
Unknown 6 1 1
Total 231 10 4 16 1 11 7
*SFG, spotted fever group; TG, typhus group. 
Table 2. Univariate and multivariate analyses of risk factors associated with SFG rickettsiosis in travelers to sub-Saharan Africa, 1996–2008* 
Univariate association  Multivariate model‡ 
Variable
Travelers with SFG 
rickettsiosis, N = 197† 
Travelers without SFG 
rickettsiosis, N = 11,690†  OR (95% CI)  p value  OR (95% CI)  p value 
Mean age, y   43.9, n = 196  36.5, n = 11,608  – <0.0001 1.02
(1.01–1.03)§ 
<0.0001
Male gender, no. (%)  115 (58.4), n = 197  6,105 (52.6), n = 11,599  1.26
(0.95–1.68) 
0.11 1.40  
(1.02–1.92) 
0.035
Travel to southern 
Africa,¶ no. (%)  
139 (70.6), n = 197  759 (6.5), n = 11,686  34.5
(25.18–47.28) 
<0.0001 23.61  
(16.86–33.07) 
<0.0001
Travel in late 
summer,# no. (%) 
89 (47.1), n = 189  4,220 (40.6), n = 10,402  1.30
(0.98–1.74) 
0.07 1.57  
(1.15–2.15) 
0.005
Travel duration >7 d, 
no. (%) 
173 (91.5), n = 189  9,661 (92.9), n = 10,402  0.83
(0.49–1.39) 
0.48 0.67  
(0.38–1.18) 
0.164
No pretravel clinic 
visit, no. (%) 
40 (21.7), n = 184  2,823 (26.5), n = 10,665  0.77
(0.54–1.10) 
0.15 0.98  
(0.66–1.44) 
0.903
Independent travel,** 
no. (%) 
34 (44.2), n = 77  4,100 (58.6), n = 6,993  0.56
(0.35–0.87) 
0.01 0.83  
(0.56–1.25) 
0.373
Tourism as reason for 
travel, no. (%)  
163 (82.7), n = 197  5,027 (43.0), n = 11,686  6.35
(4.38–9.21) 
<0.0001 2.96  
(1.97–4.45) 
<0.0001
*SFG, spotted fever group; OR, odds ratio; CI, confidence interval.  
†n = number of travelers for whom this information was available. 
‡This model included all variables considered at univariate level because of their clinical relevance. The Hosmer and Lemeshow goodness-of-fit test for 
this model is p = 0.575.  
§Odds ratio is for 1-y increase in age. 
¶United Nations subregion comprising Botswana, Lesotho, Namibia, South Africa, and Swaziland. 
#March–May. 
**Independent travel was not formally collected by GeoSentinel until after May 2007. GeoSentinel Analysis of Rickettsial Diseases
range 20–50 years). Four case-patients were tourists, 2 were 
visiting friends and relatives, 1 was a business traveler, and 
3 had traveled for other purposes. Southeast Asia, includ-
ing 3 travelers infected in Indonesia, was the most common 
region of exposure (Table 1). The median time from travel 
to reporting a site was 6 days (range 3–14 days). Five pa-
tients were hospitalized and no complications were noted. 
One patient, a 23-year-old Japanese man visiting friends 
and relatives in Bali, Indonesia, had R. typhi infection con-
ﬁ  rmed by PCR.
Indeterminate SFG/TG rickettsiosis was diagnosed in 
4 male tourists, 15, 50, 51, and 67 years of age, respec-
tively. Two case-patients were infected in Southeast Asia 
(Table 1). No complications were recorded.
The 16 travelers with scrub typhus (5 conﬁ  rmed and 
11 probable), of whom 10 were men, had a mean age of 
36.6 years (median 32.5 years; range 26–67 years). Nine 
patients were infected in Southeast Asia (including Thai-
land, n = 4) and 5 in south-central Asia (including India, n 
= 3). Twelve patients were tourists, 1 was visiting friends 
and relatives, and 3 had traveled for business. The median 
time from travel to reporting to a GeoSentinel site was 9 
days (range 2–25 days). Six case-patients were hospital-
ized. Encephalitis developed in 2 Singaporean travelers: a 
42-year-old man, a tourist infected in Thailand in Decem-
ber 2007, died, and a 51-year-old man infected in Taiwan 
while traveling on business in April 2008 survived.
An uncomplicated case of human granulocytic ana-
plasmosis was seen in August 2008 in a 32-year-old US 
woman tourist to the Netherlands. The diagnosis was based 
on detection of intracellular morulae.
The 11 travelers with acute Q fever, including 4 men, 
had a mean age of 53.0 years (median 59 years; range 20–
64 years). Sub-Saharan Africa, including 2 case-patients 
infected in Tanzania, was the most common region of ex-
posure (Table 1). Seven patients were tourists, 3 were busi-
ness travelers, and 1 had traveled for other reasons. The 
median time from travel to reporting to a site was 21 days 
(range 5–52 days). Isolated fever (n = 7) and respiratory 
symptoms (n = 4) were the most common clinical mani-
festations. Four patients were hospitalized. All 11 patients 
with Q fever had uncomplicated clinical courses. 
The 7 travelers with bartonellosis, including 3 males, 
had a mean age of 33.6 years (median 32 years, range 
9–56 years). Three patients were infected in the Caribbean 
(Table 1). Four were tourists and 3 had traveled for other 
purposes. The median time from travel to reporting to a 
GeoSentinel site was 25 days (range 7–39 days). Bartonel-
la henselae infection was diagnosed in all case-patients by 
serologic or immunohistochemical analysis. Six travelers 
had uncomplicated cat-scratch disease, and 1 had bacillary 
angiomatosis.
Discussion
This study of 280 case-patients conducted over >12 
years at 32 institutions on 5 continents represents the larg-
est series of imported rickettsial diseases published to date. 
Noteworthy, SFG rickettsiosis was by far the most com-
monly diagnosed group of disease in our study. Numerous 
SFG rickettsioses occur throughout the world, the most 
important being Mediterranean spotted fever (with its vari-
ants Indian tick typhus, Astrakhan fever, and Israeli spot-
ted fever) caused by R. conorii conorii, Rocky Mountain 
spotted fever caused by R. rickettsii, and African tick bite 
fever caused by R. africae (1). Some SFG rickettsioses may 
be accompanied by severe complications (6,7), as was ex-
empliﬁ  ed by our 2 case-patients infected in India, possibly 
representing Indian tick typhus caused by R. conorii indica 
(8). Tick-borne lymphadenopathy (TIBOLA) caused by R. 
slovaca, a recently described entity associated with Der-
macentor ticks and characterized by inoculation eschar, 
fatigue, and painful regional lymphadenitis (9), was diag-
nosed in 2 of our travelers. Being well documented across 
southern and central Europe, and especially so in children 
(10), our traveler infected in Mongolia represents the ﬁ  rst 
documented case of TIBOLA acquired in Asia and illus-
trates how travel medicine may help identify new areas of 
endemicity for infectious diseases. 
As shown here and by others (11), most cases of trav-
el-associated SFG rickettsiosis are acquired in sub-Saharan 
Africa, and particularly in South Africa and neighboring 
countries. In the present series, as many as 13.7% of all 
healthcare-seeking returnees from southern Africa had a 
diagnosis of SFG rickettsiosis (Figure 3). Although sev-
eral pathogenic SFG rickettsiae have been described in 
sub-Saharan Africa, including R. conorii, R. siberica, and 
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Figure 2. Monthly proportionate morbidity (no. cases/1,000 
travelers) of spotted fever group rickettsiosis acquired in sub-
Saharan Africa, 1996–2008.RESEARCH
R. aeschlimannii (12), 2 recent series evaluating 159 case-
patients with species-speciﬁ   c tests, including PCR and 
Western blot, suggest that >99% of SFG rickettsioses di-
agnosed in international travelers to the region are caused 
by R. africae (13,14). In 1 of these reports, game hunting as 
reason for travel, travel to southern Africa, and travel dur-
ing the summer season from November through April were 
found to be independent risk factors (14). If one assumes 
that most, if not all, of our 197 cases of SFG rickettsioses 
acquired in sub-Saharan Africa were de facto African tick 
bite fever, the present study suggests additional risk factors 
for this disease: male gender, higher age, travel during the 
late summer months of southern Africa (i.e., March–May; 
Figure 2), and travel for tourism. Although African tick bite 
fever is usually benign and self-limited, some patients may 
develop debilitating complications such as reactive arthri-
tis, cranial and peripheral neuropathies, myocarditis, and 
neuropsychiatric symptoms, or experience a long-lasting 
convalescence, the latter phenomenon recently reported in 
elderly patients (15–17). 
Our series comprises 10 cases of TG rickettsioses, 
all of which were considered to represent murine typhus 
caused by R. typhi, a bacteria transmitted from rodents 
to humans by rat ﬂ  eas in many tropical and subtropical 
areas. Murine typhus is sometimes reported in returnees 
from the Mediterranean basin, Asia, and Africa; typical 
itineraries included travel to port cities or beach resorts 
(18,19). As in the present series, most infected travelers 
have mild disease with fever and constitutional symp-
toms, but complicated cases, including deaths, have been 
reported by others (20).
We also identiﬁ  ed 16 cases of scrub typhus, a common 
disease in rural south and Southeast Asia and the Paciﬁ  c. 
Before the present report, <30 cases of travel-associated 
scrub typhus had been published in the literature, and infec-
tion was predominantly acquired in Thailand and neighbor-
ing countries (21). The disease is transmitted by the bites 
of larval trombiculid mites (chiggers) that occur year round 
on grassy vegetation and is typically acquired by campers, 
trekkers, and visitors to rice paddies (2). Although most 
cases in travelers are mild and uncomplicated, scrub typhus 
may, as exempliﬁ  ed here, result in life-threatening enceph-
alitis (22).
Human granulocytic anaplasmosis is a usually mild 
and nonspeciﬁ  c febrile illness commencing a few days af-
ter an Ixodes tick bite (23). It is endemic in North America 
and Europe with a geographic distribution that largely co-
incides with that of Lyme borreliosis. Human granulocytic 
anaplasmosis is rarely reported in international travelers 
but was recently diagnosed in an Austrian tourist visiting 
Slovenia (24). Our patient acquired the disease in 2008 in 
the Netherlands, where the ﬁ  rst domestic case was reported 
in 1999 (25).
The ubiquitous Q fever, a zoonosis typically transmit-
ted from domesticated mammals to humans by contaminat-
ed aerosols, is occasionally found in international travelers 
(26). Many infected travelers can recall visits to local farms 
and direct physical contact with domestic animals (27). All 
of our 11 case-patients had uncomplicated acute Q fever, 
the typical clinical sign in travelers, and most had a nonfo-
cal febrile illness. However, it should be noted that acute Q 
fever may be severe and even fatal in travelers (28).
Bartonelloses are rarely reported in travelers but cases 
of Carrion disease caused by Bartonella bacilliformis have 
been seen after travel to South America (29,30). In the 
present series, we identiﬁ  ed 7 case-patients likely having 
B. henselae infection, a ubiquitous condition associated 
with felines and their ﬂ  eas and not previously reported in 
international travelers. Six of our patients had cat-scratch 
disease, a self-limiting disease characterized by cutaneous 
papules or pustules at the site at the inoculation site and 
an often long-lasting painful regional lymphadenitis, and 
1 patient had bacillary angiomatosis, a potentially severe 
condition with vascular proliferation in the skin and inter-
nal organs (31).
With an overall incidence rate of 0.6% (and 1.5% of 
those travelers with fever), our analysis suggests that rick-
ettsial diseases are uncommon in ill returnees. However, 
underdiagnosis is likely to be widespread, even at special-
ized institutions such as those associated with the Geo-
Sentinel surveillance network. Few speciﬁ  c clinical signs 
exist in rickettsial diseases. Many cases have a nonfocal 
febrile disease of mild-to-moderate severity, accompanied 
by nonspeciﬁ  c results in routine blood tests (32). The in-
oculation eschar, a painless black skin lesion surrounded 
by a red halo that develops at the site of the infective tick 
or mite bite, is a useful diagnostic clue in SFG rickettsio-
ses and scrub typhus, but may be absent in <40% of such 
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Figure 3. Annual proportionate morbidity (no. cases/1,000 travelers) 
of spotted fever group rickettsiosis acquired in southern Africa, 
1996–2008. The dotted line indicates the mean value of 137/1,000 
(13.7%).GeoSentinel Analysis of Rickettsial Diseases
cases (14). The available array of microbiologic diagnostic 
tests is another predicament in the management of rickett-
sial diseases. Although sensitive and speciﬁ  c techniques, 
such as PCR and culture, can be performed at reference 
centers, most cases worldwide are diagnosed by serologic 
analysis (1). The principal limitations with serologic anal-
ysis include a usually negative result in the acute phase 
when most patients ﬁ  rst seek medical care, poor sensitivity 
in cases treated early with doxycycline, and an inability to 
distinguish between the various Rickettsia species caused 
by cross-reactions (33,34).
Some rickettsial diseases are potentially malignant, 
but severe complications developed in only a few patients 
in the present series, and only 1 traveler died. There may 
be several reasons for this favorable outcome, including a 
large percentage of benign African tick bite fever cases, 
and a widespread empiric use of antirickettsial drugs in 
cases of suspected rickettsial disease. It is noteworthy that 
rickettsial organisms are inherently resistant to many an-
timicrobial drugs commonly used as treatment for acute 
fevers, including the β-lactams, and treatment of choice is 
tetracyclines, in particular, doxycycline. Fluoroquinolones 
and newer macrolides may also be useful (1,35).
Our study had limitations similar to those in other 
GeoSentinel studies, including a possible selection bias to-
wards complicated and unusual cases (3,4). Also, because 
rickettsial diseases, with the major exceptions of Q fever 
and bartonelloses, have short incubation periods (typically 
around 1 week) some cases are likely to manifest during 
travel and may be seen only by foreign healthcare provid-
ers. An analysis solely based on persons reporting posttrav-
el is thus likely to underestimate the true incidence of rick-
ettsial diseases in international travelers. However, because 
GeoSentinel currently has no site in sub-Saharan Africa, 
the prime destination for cases of travel-associated rickett-
sial diseases, we chose to exclude cases seen during travel 
from the analysis. Lastly, because most ill returnees seen at 
GeoSentinel sites have traveled to the tropics, we may have 
underestimated the incidence of rickettsial diseases typical-
ly acquired in temperate areas, including Rocky Mountain 
spotted fever, TIBOLA, and Mediterranean spotted fever.
In summary, the present study demonstrates the wide 
spectrum of rickettsial diseases that may be encountered 
in international travelers. Most infections are acquired in 
sub-Saharan Africa, where African tick bite fever is the 
predominate disease. The overall outcome is favorable but, 
because some rickettsial diseases may take a dire course, 
empirical treatment with an antirickettsial drug should al-
ways be considered whenever evaluating a traveler with an 
otherwise unexplained febrile disease who has recently re-
turned from areas where these diseases are endemic.
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